Preclinical Development of HIV-1 Vif Antagonists - Core B

HIV-1 Vif 拮抗剂的临床前开发 - 核心 B

• 批准号: 9325577
• 负责人: Agneta von Gegerfelt
• 金额: $ 8.61万
• 依托单位: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至 2020-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9325577
• 关键词: Administrator; Agreement; Antiviral Agents; Attenuated; Cell Line; Cells; Communicable Diseases; Communication; Data; Defective Viruses; Doctor of Philosophy; Drug Kinetics; Drug Targeting; Ensure; Evaluation; Exercise; Exhibits; Funding; Goals; Grant; HIV-1; In Vitro; Individual; Industry; Institution; Instruction; Intellectual Property; Lead; Lymphoid; Macaca; Modeling; Monkeys; Mutation; Pathogenicity; Penetration; Peripheral; Persons; Phenotype; Plasma; Preparation; Progress Reports; Publications; Reagent; Research; Research Personnel; Resistance; Resistance profile; Resources; SIV; Serial Passage; Series; Site Visit; Toxic effect; Toxicology; United States National Institutes of Health; Variant; Viral reservoir; Virus; Virus Replication; Water; analog; cellular targeting; data exchange; data sharing; design; drug discovery; in vivo; inhibitor/antagonist; insight; macrophage; meetings; mutant; neuroAIDS; novel; permissiveness; preclinical development; programs; resistance mutation; response; small molecule; success; synergism; vif Genes; viral RNA; virology

Our goal of identifying novel antagonists of HlV-1 vif involves the efforts of four investigators at four different institutions. The research plan requires close communication between these groups, rapid exchange of data, research materials and reagents as well the ability to solicit input from the Scientific Advisory Board (SAB) and act on that input. These activities will be coordinated by the Administrative Core. The major functions of the Core will include: Coordinate biannual, in-person meetings between project leaders and the SAB in order to overview progress, set milestones and action items for the individual projects. Maintain budgetary oversight for the individual research components and, if necessary reallocate resources if recommended by the SAB. Promote continuous dialog between investigators engaged in the project through teleconferencing. Coordinate data sharing and the exchange of materials at different stages in the project. Coordinate preparation of progress reports to the NIH as well as an annual NIH site-visit. Coordinate the presentation of research findings at scientific meetings and publication of research findings.. Serve as an intermediary with the Commercial Ventures and Intellectual Property office ofthe participating Institutions as well as for any issues that arise through intellectual property agreements. Mario Stevenson, Ph.D. will serve as Director ofthe Administrative Core and will be assisted by Maria Pieiga who, as Administrator ofthe Division of Infectious Diseases, has extensive expertise in the oversight of NIH and Industry-funded projects.

我们鉴定HIV-1 vif的新拮抗剂的目标涉及四个不同机构的四名研究人员的努力。研究计划需要这些小组之间的密切沟通，快速交换数据，研究材料和试剂，以及征求科学咨询委员会（SAB）的意见并采取行动的能力。这些活动将由行政核心协调。核心的主要职能将包括： 协调项目负责人和SAB之间的半年一次的面对面会议，以概述进度，为各个项目设置里程碑和行动项目。 保持对各个研究部分的预算监督，并在必要时根据SAB的建议重新分配资源。 通过电话会议促进参与项目的调查人员之间的持续对话。 协调项目不同阶段的数据共享和材料交换。协调向NIH提交的进度报告的准备工作以及每年的NIH现场访问。协调在科学会议上介绍研究成果和发表研究成果。 作为参与机构的商业风险投资和知识产权办公室的中间人，以及通过知识产权协议产生的任何问题。 Mario史蒂文森博士将担任行政核心主任，并将由Maria Pieiga协助，Maria Pieiga作为传染病部的管理员，在监督NIH和行业资助项目方面具有广泛的专业知识。